Rankings
▼
Calendar
JAZZ
Jazz Pharmaceuticals plc
$12B
FY 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$4.3B
+4.9% YoY
Gross Profit
$3.8B
88.2% margin
Operating Income
$224M
5.3% margin
Net Income
-$356M
-8.3% margin
EPS (Diluted)
$-5.84
Cash Flow
Operating Cash Flow
$1.4B
Free Cash Flow
$1.3B
Stock-Based Comp.
$291M
Balance Sheet
Total Assets
$11.7B
Total Liabilities
$7.3B
Stockholders' Equity
$4.3B
Cash & Equivalents
$1.4B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$4.3B
$4.1B
+4.9%
Gross Profit
$3.8B
$3.6B
+3.9%
Operating Income
$224M
$717M
-68.7%
Net Income
-$356M
$560M
-163.6%
← Q4 2024
All Quarters
Q1 2025 →
JAZZ FY 2025 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena